Bill Gates shared his perspective on handling the salary expectation question during job interviews, advocating for a focus on long-term vision and stock options over immediate cash. In a 2020 mock ...

Petco’s second quarter results were met with a notably positive market reaction, as the company delivered profitability well above Wall Street expectations despite lower sales. Management credited the ...

Coty’s second quarter was marked by a clear negative market reaction, as the company’s results beat analyst expectations for revenue but reported positive adjusted EPS, not a loss. Management ...

Noah Berk, co-CEO of Aptitude 8, told Business Insider he values curiosity in job candidates. Berk said a candidate made a lasting impression by asking what he was reading. He said candidates should ...

The goaltending position has long been the Edmonton Oilers' Achilles heel. Despite back-to-back runs to the Stanley Cup Finals, they've dealt with tremendous inconsistencies in net, leaving everyone ...

Richard Pereira joined Newsweek in August 2025 as a Sports Writer. He earned his degree from Florida Atlantic University in 2023 and has been covering the school's athletic programs since 2020, having ...

Estée Lauder’s second quarter was marked by revenue and non-GAAP profit results that matched Wall Street expectations, but the market responded negatively due to a significant year-over-year sales ...

ScanSource’s second quarter results were driven by a higher mix of recurring revenue and continued expansion of its hybrid distribution model, which blends hardware, software, and services. While ...

Analyst Eric Balchunas said exchange-traded funds must have a futures product live for at least six months, which Canary doesn’t seem to have for its TRUMP fund. President Donald Trump’s memecoin ...

Being interviewed can be a daunting experience, often leaving you feeling on the back foot with sweaty palms. However, by shifting your mindset and attempting to stay calm in the moment, things can ...

Investing.com - Guggenheim initiated coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and a $34.00 price target on Thursday. The stock, currently trading at $16.13, has shown strong ...